本社所在地は東京都中央区日本橋本町で、2024年6月期末時点の総資産は4,932百万円、純資産は4,604百万円、株主資本は4,584百万円、自己資本比率は92.9%、発行済株式数は16,759,300株（自己株式11株を含む）である。従業員数は2024年8月末時点で39名である。Company Overview
1. Company Overview
Sasumed <4263> is a venture company in the research and development stage that aims to develop DTx, which is attracting attention as the third treatment method following pharmaceuticals and medical devices, by proposing new treatment methods, optimizing development costs through the efficiency of the drug discovery process, and streamlining the entire value chain of the pharmaceutical industry through the utilization of medical data, with the mission of providing sustainable medical services to society through the use of ICT. The name of the company is derived from "SUStainable MEDicine".
The head office is located in Nihonbashi Honcho, Chuo-ku, Tokyo, and as of the end of June 2024, the total assets were 49.32 billion yen, the net assets were 46.04 billion yen, the shareholder's equity was 45.84 billion yen, the equity ratio was 92.9%, and the number of issued shares was 16,759,300 shares (including 11 treasury shares). As of the end of August 2024, the number of employees was 39.
2. History
Sasumed established Sasumed Co., Ltd. in July 2015 and changed its organization to a corporation in February 2016. After that, it went public on the Tokyo Stock Exchange (hereinafter referred to as TSE) Mothers in December 2021, and transitioned to the TSE Growth Market in the TSE market reorganization in April 2022.
In terms of business development, in September 2016, they started clinical trials for an insomnia treatment app, and in June 2018, they started verification tests for a clinical development support system using blockchain technology. In February 2019, they started providing support services for DTx development, and in May of the same year, they started providing a machine learning automatic analysis system. In December 2021, they signed a sales partnership agreement with Shionogi <4507> regarding the insomnia treatment app, and in February 2023, they obtained manufacturing and sales approval for the insomnia treatment app medical device (which was subsequently subject to some changes in approved items in August 2024). In November 2022, they signed a contract with Kyorin Pharmaceutical <4569> for joint research and development of a treatment app in the otolaryngology field and sales after product launch, and in September 2023, they signed a contract with asuka pharmaceutical Co., Ltd. (a subsidiary of Asuka Pharmaceutical Holdings <4886>) for joint research and development of a treatment app in the obstetrics and gynecology field and sales after product launch.
(Authored by FISCO guest analyst Masanobu Mizuta)
